Piramal Pharma has informed that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of the company’s facility at Aurora, Canada from 26th May 2025 to 30th May, 2025. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation. The Company remains committed to maintain the highest standards of compliance.
The above information is a part of company’s filings submitted to BSE.